Study of Cost-Consequences Analysis Between Salbutamol With Aminophyllin For Exacerbation Asthma

2020 ◽  
Vol 1 (2) ◽  
pp. 62-69
Author(s):  
Amelia Lorensia
Keyword(s):  
Emergency Department ◽  
Data Analysis ◽  
Medical Records ◽  
Treatment Effectiveness ◽  
Cost Effective ◽  
Hospital Perspective ◽  
Asthma Exacerbations ◽  
Effectiveness Analysis ◽  
Asthma Patients ◽  
Keywords Cost

Abstract— Exacerbations asthma treatment can be done by giving medications therapy in the form of salbutamol and aminophyllin. This research conducted with a comparative study between two alternatives using a hospital perspective. Data were collected retrospectively based on the medical records of patients with mild-moderate exacerbations asthma who were admitted in emergency department Anwar Medika Sidoarjo Hospital during the period of January 2017 to Desember 2018. The data showing asthma exacerbations treatment effectiveness and costs were analyzed using ACER. Results of the data analysis using ACER based on total improvement of asthma sympthoms showed that in salbutamol group was Rp.2.403,75/%, and in aminophyllin group was Rp.1.688,31/%. Based on the result of study, cannot concluded which medications therapy were more cost-effective because total subject study of salbutamol and aminophyllin were different and too little. Results of the data analysis using ACER based on total improvement of asthma sympthoms showed that in salbutamol only group was Rp.2.073,18/%, and in salbutamol and corticosteroid group was Rp.1.688,31/%. Rp.2.573,40/%. Based on the result of ACER, salbutamol only group more cost-effective than salbutamol and corticosteroid group based on improvement of asthma sympthoms in mild-moderate exacerbations asthma patients in emergency department. Keywords: cost-effectiveness analysis, asthma exacerbations, salbutamol, aminophylline Abstrak— Pengobatan serangan asma dapat dilakukan dengan cara pemberian terapi pengobatan, yaitu salbutamol dan aminofilin. Penelitian ini merupakan penelitian yang dilakukan dengan studi perbandingan antara dua alternatif yang ada dengan menggunakan perspektif rumah sakit. Pengumpulan data dilakukan secara retrospektif berdasarkan basis data rekam medik pasien serangan asma mild moderate yang di IGD di Rumah Sakit Umum Anwar Medika Sidoarjo periode Januari 2017 sampai dengan Desember 2018. Data efektivitas dan biaya pengobatan serangan asma dianalisis dengan ACER. Dari hasil analisis data diperoleh nilai ACER berdasarkan total perbaikan gejala pada kelompok salbutamol sebesar Rp.2.403,75/%, dan kelompok aminofilin sebesar Rp.1.688,31/%. Berdasarkan hasil penelitian, tidak dapat disimpulkan terapi pengobatan yang lebih cost-effective karena jumlah subjek kelompok salbutamol dan kelompok aminofilin yang berbeda dan terlalu sedikit. Dari hasil analisis data diperoleh nilai ACER berdasarkan total perbaikan gejala pada penggunaan salbutamol tunggal sebesar Rp.2.073,18/%, pada kelompok salbutamol dan kortikosteroid sebesar Rp.2.573,40/%. Berdasarkan hasil nilai ACER tersebut, kelompok salbutamol tunggal lebih cost-effective dibandingkan kelompok salbutamol dan kortikosteroid berdasarkan perbaikan gejala pada pasien serangan asma mild moderate di IGD. Kata kunci: analisis efektivitas biaya, serangan asma, salbutamol, aminofilin

scholarly journals Cost-Effectiveness Analysis Kloramfenikol Dan Seftriakson Untuk Pengobatan Demam Tifoid Pada Pasien Dewasa Di Rumah Sakit Sanglah Denpasar

2019 ◽  
Vol 2 (2) ◽  
pp. 105-112
Author(s):  
Amelia Lorensia ◽  
Doddy De Queljoe ◽  
Made Dwike Swari Santi
Keyword(s):  
Cost Effectiveness ◽  
Length Of Stay ◽  
Typhoid Fever ◽  
Medical Records ◽  
Cost Effective ◽  
Cost Effectiveness Ratio ◽  
Hospital Perspective ◽  
Effectiveness Analysis ◽  
The Cost ◽  
Two Alternatives

The number of typhoid fever patient in Indonesia is still high. Typhoid fever can be treated by antibiotic therapy such as chloramphenicol and ceftriaxone. The purpose of this study was to compare the cost-effectiveness of chloramphenicol and ceftriaxone which was given to adult patients who were diagnosed with typhoid fever in Sanglah Denpasar Hospital. A comparative study between two alternatives was conducted using the hospital perspective. Retrospective method was used to collect data from patient medical records, who was diagnosed and hospitalized in Sanglah Denpasar Hospital during January 2017 until July 2018. The cost analysis was perform using cost-effectiveness grid and cost-effectiveness ratio (ACER) methods. Cost-effectiveness grid showed that dominant of ceftriaxone for patient with typhoid fever. ACER analysis for ceftriaxone was IDR 2,097,170.88 with effectivenes (length of stay) 4.27 days, and was IDR 2,097,170.88 with effectiveness (the time of reaching normal temperature) 2.42 days. ACER analysis for chloramphenicol was IDR 2,555,464.22        with effectivenes (length of stay) 10.22 days, and was IDR 2,555,464.22 with effectiveness (the time of reaching normal temperature) 3.44 days. ACER analysis showed lower degree of ceftriaxone and higher effectiveness based on length of stay and the time of reaching normal temperature. The conclusion of this study is that ceftriaxone is more cost-effective than chloramphenicol.

A policy of day-case sinonasal surgery is safe, well tolerated and cost-effective

2021 ◽  
pp. 1-3
Author(s):  
M Duignan ◽  
C Lao ◽  
R Lawrenson ◽  
A J Wood
Keyword(s):  
Emergency Department ◽  
Cost Effectiveness ◽  
Cost Effective ◽  
Cost Effectiveness Analysis ◽  
Day Case ◽  
Day Case Surgery ◽  
Effectiveness Analysis ◽  
Same Day Discharge ◽  
Case Surgery ◽  
The Cost

Abstract Objective Practices vary regarding the timing of discharge after sinonasal surgery. This study aimed to examine the cost-effectiveness of same-day discharge compared to next-day discharge after sinonasal surgery. Methods A retrospective single-surgeon audit of sinonasal surgery over a 12-month period was performed. Demographic and clinical details, including distance travelled home, timing of discharge, hospital re-presentation, and complications, were collected and compared between the same-day discharge and next-day discharge groups. A cost-effectiveness analysis was performed. Results A total of 181 patients were identified; 117 underwent day-case surgery, of which 6 re-presented to the emergency department. Sixty-four patients stayed overnight after surgery, and six of those patients re-presented to the emergency department. The per patient cost was $3262 for day-case sinonasal surgery and $5050 for those admitted overnight after surgery (p < 0.001). Conclusion Routine same-day discharge after sinonasal surgery is achievable, safe and cost-effective.

scholarly journals ANALISIS EFEKTIVITAS BIAYA PADA PASIEN GASTRITIS RAWAT INAP DI RUMAH SAKIT BHAYANGKARA MANADO

PHARMACON ◽  
2019 ◽  
Vol 8 (4) ◽  
pp. 767
Author(s):  
Amsaline Hutahaean ◽  
Gayatri Citraningtyas ◽  
Defny S. Wewengkang
Keyword(s):  
Cost Effectiveness ◽  
Proton Pump Inhibitor ◽  
Proton Pump ◽  
Cost Effective ◽  
Cost Effectiveness Analysis ◽  
H2 Receptor Antagonists ◽  
Medical Expenses ◽  
Effectiveness Analysis ◽  
Retrospective Data Collection ◽  
Keywords Cost

ABSTRACTGastritis is an inflammatory process in the gastric mucosa and submucosa or health problems caused by irritation and infection factors. Treatment therapy used in gastritis is the proton pump inhibitor (PPI), H2 receptor antagonists, and antacids. Giving treatment therapy used by patients has an impact on the amount of medical expenses. The purpose of this study was to determine a more cost effective therapy between the use of omeprazole and lansoprazole in hospitalized gastrtitis patients at Bhayangkara Hospital, Manado. The method used in this study is Cost Effectiveness Analysis with a retrospective data collection on the period of January - December 2018. The sample in this study was 44 patients, consisting of 25 patients using with omeprazole therapy and 19 patients with lansoprazole therapy. The results showed that the most cost-effective PPI was omeprazole with an ACER value of IDR 643,210.37 and ICER value of IDR 631,023.17/ day for each increase in effectiveness if there is a transfer from lansoprazole to omeprazole Keywords: Cost Effectiveness Analysis, Gastritis, Omeprazole, Lansoprazol. ABSTRAKGastritis adalah proses inflamasi pada mukosa dan submukosa lambung atau gangguan kesehatan yang disebabkan oleh faktor iritasi dan infeksi. Terapi pengobatan yang digunakan pada penyakit gastritis yaitu proton pump inhibitor (PPI), antagonis reseptor H2, serta antasida. Pemberian terapi pengobatan yang digunakan oleh pasien berdampak pada besarnya biaya pengobatan.  Tujuan penelitian ini untuk menentukan terapi yang lebih cost effective antara penggunaan omeprazol dan lansoprazol pada pasien gastrtitis rawat inap di RS Bhayangkaara Manado. Metode yang digunakan pada penelitian ini adalah Cost-Effectiveness Analysis dengan rancangan pengambilan data secara retrospektif pada periode Januari – Desember 2018. Sampel pada penelitian ini sebanyak 44 pasien, terdiri dari 25 pasien pengguna terapi omeprazol dan 19 pasien pengguna terapi lansoprazol. Hasil penelitian menunjukkan terapi PPI yang lebih cost-effective adalah omeprazol dengan nilai ACER sebesar Rp. 643.210,37 dan nilai ICER sebesar Rp. 631.023,17/hari untuk setiap peningkatan efektivitas jika akan dilakukan perpindahan dari lansoprazol ke omeprazol. Kata Kunci    : Analisis Efektivitas Biaya, Gastritis, Omeprazol, Lansoprazol.

Cost-Effectiveness Analysis of Combination Statin/Ezetimibe Therapy for the Treatment of Elevated Low-Density Lipoprotein Cholesterol

2005 ◽  
Vol 40 (8) ◽  
pp. 687-692 ◽  
Author(s):  
Kristen A. Gryskiewicz ◽  
Craig I. Coleman ◽  
Effie L. Gillespie ◽  
C. Michael White
Keyword(s):  
Cost Effectiveness ◽  
Drug Cost ◽  
Disease Risk ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Cost Effective ◽  
Cost Effectiveness Analysis ◽  
Lipid Lowering ◽  
Hospital Perspective ◽  
Effectiveness Analysis

Purpose Although statins have been shown to reduce LDL-C and coronary heart disease risk, it is not uncommon for patients to fail to reach NCEP ATP III goals. Some statins cannot lower LDL-C sufficiently; others cannot be titrated optimally due to drug interactions and adverse effects. Concomitant ezetimibe administration can augment LDL-C reduction over statin monotherapy; however, multidrug therapy may result in additional expense. Methods We conducted a cost-effectiveness analysis (CEA) from the hospital perspective including all FDA approved statins alone (fluvastatin, lovastatin, pravastatin, simvastatin, rosuvastatin, or atorvastatin) or the following statins plus ezetimibe: lovastatin, pravastatin, simvastatin, or atorvastatin. LDL-C lowering efficacy was determined from clinical trials. Our institution's actual acquisition cost was used to approximate drug cost (US $2,004) for each statin dose alone and with ezetimibe. To test the robustness of our results a Monte Carlo simulation was conducted varying both the cost of drug and percent LDL-C reduction efficacy. Results For patients requiring less than or equal to 40% reduction from baseline in LDL-C, lovastatin 10, 20, or 40 mg, or fluvastatin 80 mg would appear to be reasonable choices based upon both efficacy and cost data. For reductions in LDL-C in the range of greater than 40%; simvastatin 40 mg plus ezetimibe 10 mg was found to be most cost effective; although, simvastatin 80 mg, rosuvastatin 20 or 40 mg, or simvastatin 80 mg plus ezetimibe 10 mg appear to be reasonably cost-effective as well. These results were not found to be robust to variations in drug cost and LDL-C reduction. Conclusion When smaller reductions in LDL-C are required (less than 40%), drug cost is the variable that most significantly drives cost effectiveness; however, when larger LDL-C reductions are required, LDL-C lowering capacity is the single most important factor in determining cost-effectiveness of the lipid-lowering therapies. The addition of ezetimibe becomes most cost-effective when larger reductions are required.

scholarly journals A pharmacoeconomic study of traditional anticoagulation versus direct oral anticoagulation for the treatment of venous thromboembolism in the emergency department

CJEM ◽  
2016 ◽  
Vol 18 (5) ◽  
pp. 340-348 ◽  
Author(s):  
Stephanie Law ◽  
Daljit Ghag ◽  
Eric Grafstein ◽  
Robert Stenstrom ◽  
Devin Harris
Keyword(s):  
Emergency Department ◽  
Venous Thromboembolism ◽  
Patient Perspective ◽  
Cost Minimization ◽  
Cost Effective ◽  
Pharmacoeconomic Study ◽  
International Normalized Ratio ◽  
Patient Perspectives ◽  
Therapeutic Monitoring ◽  
Hospital Perspective

AbstractObjectivesPatients with venous thromboembolism (VTE) (deep vein thrombosis [DVT] and pulmonary embolism [PE]) are commonly treated as outpatients. Traditionally, patients are anticoagulated with low-molecular-weight heparin (LMWH) and warfarin, resulting in return visits to the ED. The direct oral anticoagulant (DOAC) medications do not require therapeutic monitoring or repeat visits; however, they are more expensive. This study compared health costs, from the hospital and patient perspectives, between traditional versus DOAC therapy.MethodsA chart review of VTE cases at two tertiary, urban hospitals from January 1, 2010 to December 31, 2012 was performed to capture historical practice in VTE management, using LMWH/warfarin. This historical data were compared against data derived from clinical trials, where a DOAC was used. Cost minimization analyses comparing the two modes of anticoagulation were completed from hospital and patient perspectives.ResultsOf the 207 cases in the cohort, only 130 (63.2%) were therapeutically anticoagulated (international normalized ratio 2.0–3.0) at emergency department (ED) discharge; patients returned for a mean of 7.18 (range: 1–21) visits. Twenty-one (10%) were admitted to the hospital; 4 (1.9%) were related to VTE or anticoagulation complications. From a hospital perspective, a DOAC (in this case, rivaroxaban) had a total cost avoidance of $1,488.04 per VTE event, per patient. From a patient perspective, it would cost an additional $204.10 to $349.04 over 6 months, assuming no reimbursement.ConclusionsVTE management in the ED has opportunities for improvement. A DOAC is a viable and cost-effective strategy for VTE treatment from a hospital perspective and, depending on patient characteristics and values, may also be an appropriate and cost-effective option from a patient perspective.

scholarly journals Efektivitas Biaya Penggunaan Antibiotik Pasien ISPA Pediatri di RSUD Kajen Kabupaten Pekalongan Tahun 2019

2021 ◽  
Vol 1 ◽  
pp. 108-116
Author(s):  
Siti Aliyah ◽  
Yulian Wahyu Permadi ◽  
St Rahmatullah ◽  
Ainun Mutoharoh
Keyword(s):  
Cost Effective ◽  
Average Total Cost ◽  
Medical Record Data ◽  
Cost Of Treatment ◽  
Total Cost ◽  
Effectiveness Analysis ◽  
Record Data ◽  
Acute Infectious Disease ◽  
The Cost ◽  
Keywords Cost

AbstractAcute respiratory infection (ARI) is an acute infectious disease that attacks one or more parts of the respiratory system, starting from the nasal alveoli, including the adnexa (sinus of the pleural middle ear cavity). The purpose of this study was to determine the type of antibiotics in pediatric ARI patients at Kajen Hospital in 2019 and to determine the effectiveness of treatment costs based on the use of antibiotics issued by pediatric ARI patients at Kajen Hospital in 2019. This study is a type of non-experimental research that is descriptive and takes retrospectively through medical record data of ARI patients. The number of samples used as many as 80 patients. The pharmacoeconomic method used in this study is the CEA method/cost effectiveness analysis. The data taken include: data on respondent characteristics, total costs or direct medical costs, the results of the study on the effectiveness of antibiotic therapy Cefotaxim 52.90%, Efotax 54.50% and Viccillin 61.50%. The average total cost of antibiotics for Cefotaxim was Rp. 817,392, Efotax was Rp. 1,392,189, Viccillin was Rp. 1,318,838, Ampicillin was Rp. 1,107,059, Cefadroxil was Rp. 850,564 and Cefixim was Rp. 858,479. The ACER value was the most cost effective for Cefotaxim compared to other therapies. while the ICER value is the most cost effective, namely the comparison between Cefotaxim and Viccillin with an ICER value of Rp - 63,081,937. Suggestions for further research are expected to be able to compare the cost of treatment for outpatients and inpatients and increase sampledata. Keywords: Cost Effectiviness, ARI, antibiotik AbstrakInfeksi saluran pernafasan akut (ISPA) merupakan penyakit infeksi akut yang menyerang salah satu / lebih bagian dari sistem pernafasan mulai dari hidung alveoli termasuk adneksanya (sinus rongga telinga tengah pleura). Tujuan penelitian ini adalah untuk mengetahui jenis antibiotik pada pasien ISPA pediatri di RSUD Kajen tahun 2019 dan untuk mengetahui keefektifan biaya pengobatan berdasarkan penggunaan antibiotik yang dikeluarkan oleh pasien ISPA pediatri di RSUD kajen tahun 2019. Penelitian ini merupakan jenis penelitian non eksperimental yang bersifat deskriptif dan pengambilan data secara retrospektif melalui data rekam medik pasien ISPA. Jumlah sampel yang digunakan sebanyak 80 pasien. Metode farmakoekonomi yang digunakan pada penelitian ini yaitu metode CEA/Analisis efektifitas biaya. Data yang diambil meliputi: data karakteristik responden, biaya total atau biaya medik langsung, Hasil penelitian efektivitas terapi antibiotik Cefotaxim 52,90%, Efotax 54,50% dan Viccillin 61,50%. Hasil rata-rata total biaya antibiotik Cefotaxim sebesar Rp 817.392, Efotax Rp 1.392.189, Viccillin Rp 1.318.838, Ampicillin Rp 1.107.059, Cefadroxil Rp 850.564 dan Cefixim Rp 858.479. Nilai ACER yang paling cost efffective pada antibiotik Cefotaxim dibandingkan dengan terapi lainnya. sedangkan pada nilai ICER yang paling cost effecttive yaitu pada perbandingan antara Cefotaxim dengan Viccillin dengan nilai ICER Rp - 63.081.937. Saran untuk penelitian selanjutnya diharapkan dapat membandingkan biaya pengobatan pasien rawat jalan dan rawat inap serta memperbanyak data sampelKata kunci: Efektivitas biaya; ISPA; antibiotik

scholarly journals COST-EFFECTIVENESS ANALYSIS OF CEFTAZIDIME-LEVOFLOXACIN AND CEFOTAXIME-ERYTHROMYCIN AS EMPIRICAL ANTIBIOTIC COMBINATIONS IN RESPIRATORY INFECTION-INDUCED SEPSIS

2017 ◽  
Vol 10 (14) ◽  
pp. 119
Author(s):  
Dika P Destiani ◽  
Tiana Milanda ◽  
Susilawati Susilawati ◽  
Auliya A Suwantika ◽  
Ivan S Pradipta ◽  
...  
Keyword(s):  
Respiratory Infection ◽  
Medical Records ◽  
Public Hospital ◽  
Cost Effective ◽  
Fixed Cost ◽  
Significant Parameter ◽  
Effectiveness Analysis ◽  
Number Of Patients ◽  
Major Treatment ◽  
Selection Of

Objective:Pharmacoeconomics has become an important consideration in the selection of therapies, including in patients with sepsis caused by respiratory infection. The aim of this study was to determine the most cost-effective antibiotic combination for respiratory infection-induced sepsis at a public hospital in Bandung, Indonesia.Methods:This retrospective observational study was conducted at one ofpublic hospitals in Bandung. Two interventions were analyzed: (I1) ceftazidime-levofloxacin  and (I2) cefotaxime-erythromycin; and compared to the major treatment (I0, the use of other antibiotic combinations). Data were collected from the medical records of inpatients with respiratory infection-induced sepsis from 2010 until 2012. Healthcare perspective was applied by considering only direct medical costs, which were calculated from variable (drug, administrative andtreatment cost) and fixed cost (hospitalization).Results:Comparing with I0, net cost per life saved was calculated to be $3,350 (I1)and $1,589 (12). Number of patients survived was considered to be the most significant parameter on affecting the calculation of net cost per life saved.Conclusion:I2 was more cost effective than I1, compared to I0.  

scholarly journals ANALISIS EFEKTIVITAS BIAYA PADA PASIEN INFEKSI SALURAN KEMIH (ISK) RAWAT INAP DI RUMAH SAKIT BHAYANGKARA MANADO

PHARMACON ◽  
2019 ◽  
Vol 8 (1) ◽  
pp. 234
Author(s):  
Gabrilia P. C. Sukandi ◽  
Gayatri Citraningtyas ◽  
Paulina V. Y. Yamlean
Keyword(s):  
Urinary Tract ◽  
Urinary Tract Infections ◽  
Cost Effective ◽  
Upper Urinary Tract ◽  
Descriptive Research ◽  
Effectiveness Analysis ◽  
Retrospective Data Collection ◽  
Cost Categories ◽  
Tract Infections ◽  
Keywords Cost

ABSTRACT Urinary tract infections are a clinical condition due to the presence of microorganisms in the urine and the potential for invasion of the upper urinary tract, invading the renal pelvic mucosa and extending into the interstitial tissues of the kidneys. Urinary tract infections treated with antibiotics are one of the significant cost categories in the pharmaceutical budget in hospitals. The purpose of this study was to determine a more cost effective therapy between the use of Ceftriaxone and Ciprofloxacin in UTI patients hospitalized at Bhayangkara Hospital, Manado. This study uses a descriptive research method with retrospective data collection. The sample in this study were 36 patients including 15 patients using Ceftriaxone and 21 patients using Ciprofloxacin. The results showed that the most cost-effective  antibiotic was Ceftriaxone with an ACER value of IDR 781,890 and ICER value of IDR 551,255. Keywords: Cost Effectiveness Analysis, Urinary Tract Infections, Ceftriaxone, Ciprofloxacin. ABSTRAK Infeksi saluran kemih adalah keadaan klinis akibat adanya mikroorganisme dalam urin dan berpotensi untuk invasi ke saluran kemih bagian atas, menginvasi mukosa pelvis ginjal dan meluas ke dalam jaringan interstisial ginjal. Infeksi saluran kemih diobati dengan antibiotik yang menjadi salah satu kategori biaya yang signifikan dalam anggaran farmasi di rumah sakit. Tujuan penelitian ini untuk menentukan terapi yang lebih cost effective antara penggunaan Seftriakson dan Siprofloksasin pada pasien ISK rawat inap di RS Bhayangkara Manado. Penelitian ini menggunakan metode penelitian deskriptif dengan pengambilan data secara retrospektif. Sampel pada penelitian ini sebanyak 36 pasien diantaranya15 pasien menggunakan Seftriakson dan 21 pasien menggunakan Siprofloksasin. Hasil penelitian menunjukan, antibiotik yang paling cost-effective adalah Seftriakson dengan nilai ACER sebesar Rp. 781.890 dan nilai ICER sebesar Rp. 551.255. Kata Kunci : Analisis Efektivitas Biaya, Infeksi Saluran Kemih, Seftriakson, Siprofloksasin

Analysis of Deliberate Self-Wrist-Cutting Episodes Presenting to the Emergency Department

Crisis ◽  
2016 ◽  
Vol 37 (2) ◽  
pp. 155-160 ◽  
Author(s):  
Jin Kim ◽  
Han Joon Kim ◽  
Soo Hyun Kim ◽  
Sang Hoon Oh ◽  
Kyu Nam Park
Keyword(s):  
Emergency Department ◽  
Medical Records ◽  
Attempted Suicide ◽  
Suicide Attempts ◽  
Psychiatric Interview ◽  
Clinical Variables ◽  
Completed Suicide ◽  
Number Of Patients ◽  
Group A ◽  
Efficacy Of Treatment

Abstract. Background: Previous suicide attempts increase the risk of a completed suicide. However, a large proportion of patients with deliberate self-wrist cutting (DSWC) are often discharged without undergoing a psychiatric interview. Aims: The aims of this study were to investigate the differences in the characteristics and outcomes of patients with DSWC and those with deliberate self-poisoning (DSP) episodes. The results of this study may be used to improve the efficacy of treatment for DSWC patients. Method: We retrospectively reviewed the medical records of 598 patients with DSWC and DSP who were treated at the emergency department of Seoul Saint Mary's Hospital between 2008 and 2013. We assessed sociodemographic information, clinical variables, the reasons for the suicide attempts, and the severity of the suicide attempts. Results: A total of 141 (23.6%) patients were included in the DSWC group, and 457 (76.4%) were included in the DSP group. A significantly greater number of patients in the DSWC group had previously attempted suicide (p = .014). A total of 63 patients (44.7%) in the DSWC group and 409 patients (89.5%) in the DSP group underwent psychiatric interviews. Conclusion: More DSWC patients had previously attempted suicide, but fewer of them underwent psychiatric interviews compared with the DSP patients.

The WHO World Mental Health (WMH) Surveys

2009 ◽  
Vol 06 (01) ◽  
pp. 5-9 ◽  
Author(s):  
S. Aguilar-Gaxiola ◽  
J. Alonso ◽  
S. Chatterji ◽  
S. Lee ◽  
T. B. Üstün ◽  
...  
Keyword(s):  
Mental Health ◽  
Mental Disorders ◽  
Treatment Effectiveness ◽  
Age Of Onset ◽  
Common Mental Disorders ◽  
Mental Health Policy ◽  
Unmet Need ◽  
Cost Effective ◽  
World Mental Health ◽  
Prevalence Estimates

SummaryThe paper presents an overview of the WHO World Mental Health (WMH) Survey Initiative and summarizes recent WMH results regarding the prevalence and societal costs of mental disorders. The WMH surveys are representative community surveys that were carried out in 28 countries throughout the world aimed at providing information to mental health policy makers about the prevalence, burden, and unmet need for treatment of common mental disorders. Results show that mental disorders are commonly occurring in all participating countries. The inter-quartile range (IQR: 25th-75th percentiles) of lifetime DSM-IV disorder prevalence estimates (combining anxiety, mood, disruptive behavior, and substance disorders) is 18.1-36.1%. The IQR of 12-month prevalence estimates is 9.8-19.1%. Analysis of age-of-onset reports shows that many mental disorders begin in childhood-adolescence and have significant adverse effects on subsequent role transitions. Adult mental disorders are found in the WMH data to be associated with high levels of role impairment. Despite this burden, the majority of mental disorders go untreated. Although these results suggest that expansion of treatment could be cost-effective from both the employer perspective and the societal perspective, treatment effectiveness trials are needed to confirm this suspicion. The WMH results regarding impairments are being used to target several such interventions.

Sign in / Sign up

Export Citation Format

Share Document